Wave Life Sciences

Update in progress

WVE (NasdaqGM)

Company RatingNeutral
SectorHealthcare
IndustryBiotechnology

Wave Life Sciences is a clinical-stage biotech company designing RNA medicines with its PRISM platform, blending modalities, chemistry innovation, and human-genetics insights to treat rare and common diseases. It advances WVE-006 for alpha-1 antitrypsin deficiency, WVE-007 for obesity, WVE-008 for liver disease, WVE-N531 for Duchenne muscular dystrophy, and WVE-003 for Huntington's disease. Partners include GSK, Takeda, and Asuragen. Founded 2012, Singapore.

Company score

Sentiment: 0.41; SentimentMeasures the overall tone of recent coverage and discussion about the company.−10 negative · 0 neutral · +10 positive
Environment: 0.00; EnvironmentAssesses the company’s environmental impact, risks, and sustainability practices.−10 negative · 0 neutral · +10 positive
Social: 0.34; SocialAssesses the company’s influence on employees, customers, communities, and wider society.−10 negative · 0 neutral · +10 positive
Governance: 0.08; GovernanceAssesses leadership, accountability, transparency, and business ethics.−10 negative · 0 neutral · +10 positive
Sustainability: 0.12; SustainabilityCombines environmental, social, and governance signals into an overall sustainability score.−10 negative · 0 neutral · +10 positive
Impact Score: 0.26; Impact ScoreCombines sentiment and sustainability performance into an assessment of the company’s overall impact.−10 negative · 0 neutral · +10 positive